Inactive Instrument

Prometheus Biosciences, Inc.

Equities

RXDX

US74349U1088

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
S&P 500 Posts Weekly Decline Led by Real Estate, Energy as Fed Officials Point to More Rate Increases MT
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P Global BMI Index CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P TMI Index CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P Biotechnology Select Industry Index CI
Global markets live: Adobe, Eli Lilly, Nasdaq, Intel, UBS... Our Logo
Paris-listed Drugmaker Merck & Co. Buys Prometheus Biosciences MT
Prometheus Biosciences, Inc.(NasdaqGM:) dropped from NASDAQ Composite Index CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from NASDAQ Biotechnology Index CI
Merck & Company Completes Acquisition of Prometheus Biosciences for $10.8 Billion in Cash; to Cut EPS Outlook in August MT
Prometheus Biosciences, Inc. Announces Management Changes CI
Prometheus Biosciences, Inc. Announces Cessation of Mark C. McKenna as CEO CI
Prometheus Biosciences, Inc. Announces Cessation of Keith W. Marshall as CFO CI
Merck & Co., Inc. completed the acquisition of Prometheus Biosciences, Inc. from a group of shareholders. CI
Analysis-Amgen's antitrust woes spur wider pharmaceutical deal fears RE
US FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics RE
North American Morning Briefing : Stock Futures -3- DJ
Jefferies Downgrades Prometheus Biosciences to Hold From Buy, Adjusts Price Target to $200 From $160 MT
Prometheus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (RXDX) PROMETHEUS BIOSCIENCES Reports Q1 Revenue $1.1M MT
Merck & Co. Files Six-Part Shelf Offering of Unsecured Senior Debt Obligation Notes MT
Drugmakers scout for deals, ramp up research spending RE
North American Morning Briefing : Sentiment -3- DJ
Global markets live: EasyJet, Bank of America, Goldman Sachs, J&J, Alphabet... Our Logo
Credit Suisse Downgrades Prometheus Biosciences to Neutral From Outperform on Heels of Announced Sale to Merck & Co., Raises Price Target to $200 From $139 MT
RBC Downgrades Prometheus Biosciences to Sector Perform From Outperform, Lifts Price Target to $200 From $140 on Merck Deal; Speculative Risk Kept MT
Chart Prometheus Biosciences, Inc.
More charts
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
More about the company
  1. Stock
  2. Equities
  3. Stock Prometheus Biosciences, Inc. - Nyse
  4. News Prometheus Biosciences, Inc.
  5. Prometheus Biosciences : Oppenheimer Starts Prometheus Biosciences at Outperform With $35 Price Target